Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity

DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort

(2020) Elizabeth C. Verna et al.   JOURNAL OF HEPATOLOGY

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

(2020) Sabela Lens et al.   JOURNAL OF HEPATOLOGY

Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct‐Acting Antiviral Era

(2019) Thomas G. Cotter et al.   LIVER TRANSPLANTATION

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

(2019) Fabrice Carrat et al.   LANCET

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection

(2018) Omar El-Sherif et al.   GASTROENTEROLOGY

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

(2018) Pierre Nahon et al.   GASTROENTEROLOGY

Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease

(2018) Lisa I. Backus et al.   HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2018

(2018) Jean-Michel Pawlotsky et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

(2018) Paolo Angeli et al.   JOURNAL OF HEPATOLOGY

Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis

(2017) Sabela Lens et al.   GASTROENTEROLOGY

Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation

(2017) Juan Manuel Pascasio et al.   JOURNAL OF HEPATOLOGY

Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension

(2017) N. Afdhal et al.   JOURNAL OF VIRAL HEPATITIS

Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients

(2017) James M. Neuberger et al.   TRANSPLANTATION

Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis

(2016) Raoel Maan et al.   Clinical Gastroenterology and Hepatology

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

(2016) Fred Poordad et al.   HEPATOLOGY

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study

(2016) Luca Saverio Belli et al.   JOURNAL OF HEPATOLOGY

Reversion of disease manifestations after HCV eradication

(2016) Adriaan J. van der Meer et al.   JOURNAL OF HEPATOLOGY

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

(2016) Mattias Mandorfer et al.   JOURNAL OF HEPATOLOGY

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

(2016) Graham R. Foster et al.   JOURNAL OF HEPATOLOGY

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

(2016) Michelle C.M. Cheung et al.   JOURNAL OF HEPATOLOGY

Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era

(2016) S. A. McDonald et al.   JOURNAL OF VIRAL HEPATITIS

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

(2016) Michael Manns et al.   LANCET INFECTIOUS DISEASES

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

(2015) Michael Charlton et al.   GASTROENTEROLOGY

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

(2015) Michael P. Curry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

(2015) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis

(2014) Jonathan G. Stine et al.   DIGESTIVE DISEASES AND SCIENCES

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

(2014) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

(2013) Adriaan J. van der Meer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)

(2013) Thierry Poynard et al.   JOURNAL OF HEPATOLOGY

Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study

(2012) M.-H. Lee et al.   JOURNAL OF INFECTIOUS DISEASES

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

(2011) Elena Vezali et al.   CLINICAL THERAPEUTICS

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus

(2009) Amit G. Singal et al.   Clinical Gastroenterology and Hepatology

Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

(2008) Mireen Friedrich–Rust et al.   GASTROENTEROLOGY